Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.ebiom.2020.102768
DC Field | Value | |
---|---|---|
dc.title | Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development | |
dc.contributor.author | de Alwis, R. | |
dc.contributor.author | Chen, S. | |
dc.contributor.author | Gan, E.S. | |
dc.contributor.author | Ooi, E.E. | |
dc.date.accessioned | 2021-08-19T04:28:56Z | |
dc.date.available | 2021-08-19T04:28:56Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | de Alwis, R., Chen, S., Gan, E.S., Ooi, E.E. (2020). Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine 55 : 102768. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ebiom.2020.102768 | |
dc.identifier.issn | 2352-3964 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/197902 | |
dc.description.abstract | The pandemic spread of a novel coronavirus – SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle – the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis. © 2020 The Author(s) | |
dc.publisher | Elsevier B.V. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Scopus OA2020 | |
dc.subject | Coronavirus | |
dc.subject | COVID-19 | |
dc.subject | Polyclonal hyperimmune globulin | |
dc.subject | SARS-CoV-2 | |
dc.subject | Vaccines | |
dc.type | Review | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1016/j.ebiom.2020.102768 | |
dc.description.sourcetitle | EBioMedicine | |
dc.description.volume | 55 | |
dc.description.page | 102768 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1016_j_ebiom_2020_102768.pdf | 674.36 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License